In July 2021, Stop TB Partnership’s Executive Committee approved US$6.14 million for Wave 9 funding to be awarded to 11 projects, in 8 countries, to focus their efforts on innovative approaches to address drug resistant tuberculosis (DR-TB).With funding support from USAID and Global Affairs Canada, TB REACH Wave 9 grantees will help reduce initial or pre-treatment loss to follow up for people with DR-TB, by expanding access to new, all-oral treatment regimens, and improving treatment adherence and outcomes for people with DR-TB.
In Wave 9, only local, non-governmental organizations were eligible for funding, and together with the support of USAID, TB REACH will work with the organizations on a capacity assessment as part of a development plan to help grantees to improve and continue their funding efforts.
The Wave 9 Call for Proposals was launched in January 2021 and received almost 300 applications from 24 countries with a total funding request of USD 145 million. All completed proposals were reviewed intensively by an independent Proposal Review Committee (PRC), who selected 48 applicants to be invited to submit a more in-depth stage 2 proposal. These applications underwent another round of diligent and careful review by the PRC. After an 8-day review meeting, the PRC recommended 11 projects from 8 countries for funding.
TB REACH Wave 9 Grantees
|Country||Grantee Organization||Requested Budget|
|Category: Implementation of new DR-TB treatment regimens|
|Bangladesh||Interactive Research & Development Ltd.||$ 600’000|
|Viet Nam||CTY TNHH (IRD VN)||$ 600’000|
|Zimbabwe||The Union Zimbabwe Trust||$ 599’995|
|Category: Improving treatment adherence and outcomes|
|Pakistan||DOPASI Foundation||$ 598’819|
|Category: Linkage to care to reduce pre-treatment loss to follow-up|
|India||Innovators In Health (India)||$ 593’066|
|India||Resource Group for Education and Advocacy for Community Health||$ 584’286|
|Nigeria||RedAid Nigeria||$ 213’459|
An interactive map of TB REACH projects can be seen with all the projects listed, click here.